Journal of the American Society of Nephrology, Vol 2, 1130-1135, Copyright © 1991 by American Society of Nephrology

REGULAR ARTICLES

Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis

TR Ziegler, JM Lazarus, LS Young, R Hakim and DW Wilmore
Laboratory of Surgical Metabolism and Nutrition, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.

Administration of recombinant human growth hormone stimulates protein synthesis, decreases urea generation, and improves nitrogen balance in individuals with normal renal function. However, little information is available concerning the effects of growth hormone in patients with renal disease. This pilot study evaluated urea kinetics and clinical/metabolic responses to short-term growth hormone administration in five clinically stable adult patients requiring maintenance hemodialysis for end-stage renal failure. The dialysis prescription, medications, and oral calorie and protein intake of each patient remained constant during an initial control week and a subsequent 2-wk growth hormone treatment period. During treatment, growth hormone (5 or 10 mg) was administered s.c. immediately after each dialysis session. Protein and calorie intake, vital signs, body weight, and other clinical parameters remained stable throughout the 3- wk study. BUN values fell significantly (approximately 20 to 25%) during growth hormone administration compared with control week values. Similarly, urea kinetic modeling demonstrated a significant reduction in urea generation and the protein catabolic rate during each week of growth hormone treatment. Plasma insulin-like growth factor I levels rose significantly, and serum phosphorus and intact parathyroid hormone levels fell significantly during growth hormone administration. Serum glucose and other blood values remained stable. This preliminary study suggests that growth hormone administration reduces urea generation and improves the efficiency of dietary protein utilization in stable adult hemodialysis patients. Growth hormone may be a useful adjunctive therapy to diminish body protein catabolism in this patient population.

This article has been cited by other articles:

				J. D. Kopple, A. K. Cheung, J. S. Christiansen, C. B. Djurhuus, M. El Nahas, B. Feldt-Rasmussen, M. Lange, W. E. Mitch, C. Wanner, J. Wiedemann, et al. OPPORTUNITYTM: A Randomized Clinical Trial of Growth Hormone on Outcome in Hemodialysis Patients Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1741 - 1751. [Abstract] [Full Text] [PDF]

				B. Feldt-Rasmussen, M. Lange, W. Sulowicz, U. Gafter, K. N. Lai, J. Wiedemann, J. S. Christiansen, M. El Nahas, and and the Adult Patients in Chronic Dialysis (APCD) Growth Hormone Treatment during Hemodialysis in a Randomized Trial Improves Nutrition, Quality of Life, and Cardiovascular Risk J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2161 - 2171. [Abstract] [Full Text] [PDF]

				L. B Pupim, P. J Flakoll, C. Yu, and T A. Ikizler Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients Am. J. Clinical Nutrition, December 1, 2005; 82(6): 1235 - 1243. [Abstract] [Full Text] [PDF]

				J. D. Kopple, G. Brunori, M. Leiserowitz, and D. Fouque Growth hormone induces anabolism in malnourished maintenance haemodialysis patients Nephrol. Dial. Transplant., May 1, 2005; 20(5): 952 - 958. [Abstract] [Full Text] [PDF]

				G. Akner and T. Cederholm Treatment of protein-energy malnutrition in chronic nonmalignant disorders Am. J. Clinical Nutrition, July 1, 2001; 74(1): 6 - 24. [Abstract] [Full Text] [PDF]

				P. Iglesias, R. Selgas, J. Mendez, M. J. Fernandez-Reyes, M. A. Bajo, A. Aguilera, and J. J. Diez Short-term recombinant human growth hormone therapy does not modify growth hormone, thyrotropin and prolactin responses to thyrotropin-releasing hormone in adult dialysis patients Nephrol. Dial. Transplant., June 1, 2000; 15(6): 856 - 861. [Abstract] [Full Text] [PDF]

				M. R. Hammerman `The growth hormone–insulin-like growth factor axis in kidney re-revisited Nephrol. Dial. Transplant., August 1, 1999; 14(8): 1853 - 1860. [Full Text] [PDF]

				K. L. Johansen, K. Mulligan, and M. Schambelan Anabolic Effects of Nandrolone Decanoate in Patients Receiving Dialysis: A Randomized Controlled Trial JAMA, April 14, 1999; 281(14): 1275 - 1281. [Abstract] [Full Text] [PDF]

				W. W. Souba Nutritional Support N. Engl. J. Med., January 2, 1997; 336(1): 41 - 48. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673